# ARTIVION, INC. (AORT) — Financial Analysis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-06-17  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/aort/thesis · /memo/aort

## Financial Snapshot

---
source: coverage-next-full
step: 04
ticker: AORT
company: Artivion, Inc.
date: 2026-06-15
---

### Step 04 — Financial Snapshot & Quality: Artivion, Inc. (AORT)

#### 1. Income Statement Quality Analysis

##### Revenue Recognition
Artivion recognizes product revenue upon delivery/transfer of title to the customer, following ASC 606. Preservation services revenue recognized upon tissue shipment. No material contingent revenue arrangements noted. **Revenue recognition appears conservative and appropriate for the business model.** [S1]

##### Gross Margin Stability

| Year | Revenue | Gross Profit | Gross Margin |
|------|---------|-------------|-------------|
| FY2019 | $276.2M | $183.0M | 66.3% |
| FY2020 | $253.2M | $167.8M | 66.3% |
| FY2021 | $298.8M | $197.5M | 66.1% |
| FY2022 | $313.8M | $202.5M | 64.5% |
| FY2023 | $354.0M | $229.2M | 64.7% |
| FY2024 | $388.5M | $248.8M | 64.0% |
| FY2025 | $441.3M | $284.2M | 64.4% |

*Source: [S2] XBRL company facts*

**Observation:** Gross margins have compressed ~2pp from the 66%+ range pre-2022. The shift reflects the higher COGS associated with the JOTEC stent graft portfolio (more complex manufacturing) versus legacy tissue services. Margins have stabilized in the 64–65% band over the last three years — this appears to be the new normalized range. No material revenue-recognition manipulation evident.

##### Operating Expense Concerns

SG&A is exceptionally high at **51.3% of revenue ($226.5M)** in FY2025. This is characteristic of direct-selling medical device companies with heavy clinical support infrastructure, but it is notably above med-tech peers. R&D at 7.0% ($31M) is appropriate for an active pipeline company. [S1]

**Red flag:** SG&A absorbs nearly all gross profit. The operating income of $33.7M (7.6% margin) is positive but thin — and below FY2024's $38.9M despite $52.8M more revenue. This suggests SG&A grew faster than revenue in FY2025. Possible explanations: NEXUS pre-commercial launch spend, Endospan integration costs, FX headwinds in European sales force.

##### Non-Cash Items

| Item | Magnitude | Impact on True Earnings |
|------|----------|------------------------|
| Amortization of acquisition intangibles | ~$25M/yr (est.) | Depresses GAAP earnings but is non-cash |
| Stock-based compensation (SBC) | ~$24M/yr (est.) | Cash dilution; management uses adj. EPS excluding SBC |
| Goodwill ($254M at Q1 2026) | Impairment risk on Preservation Services | Monitor for segment writedown |

**Adjusted EBITDA bridge:** From $33.7M GAAP operating income + ~$25M D&A + ~$24M SBC + other adj = ~$82–90M adj. EBITDA (~20% margin). Management's reported adj. EBITDA of ~$89–90M in FY2025 is internally consistent. [S1]

---

#### 2. Balance Sheet Quality

##### Debt and Leverage

| Metric | Dec 2023 | Dec 2024 | Dec 2025 | Q1 2026 |
|--------|---------|---------|---------|---------|
| Cash | $59M | $53M | $65M | $56M |
| Long-Term Debt | $307M | $314M | $215M | $215M |
| Net Debt | $248M | $261M | $150M | $159M |
| Total Assets | $792M | $789M | $885M | $883M |
| Stockholders' Equity | $282M | $276M | $448M | $450M |

*Source: [S2] XBRL*

**Leverage reduction was dramatic in H1 2025:** Long-term debt fell from $314M (Dec 2024) to $215M (Dec 2025) — a $99M reduction driven by the secondary equity offering (shares grew from ~41.7M to ~47.2M diluted). This de-risked the balance sheet substantially. Debt/EBITDA declined from ~3.8x to ~1.7x. [S1]

**Post-Endospan re-levering (May 2026):** The Endospan acquisition ($135M upfront) is expected to re-lever the balance sheet. This transaction closed after the FY2025 period, so the balance sheet impact will not appear until Q2 2026. Estimated post-deal net debt: ~$290–310M, implying Debt/EBITDA back to ~2.8–3.0x on adj. EBITDA of ~$100–107M FY2026 guidance. Manageable, but a near-term constraint on financial flexibility. [S4]

##### Goodwill and Intangibles

- Goodwill: $254M (Q1 2026) — primarily from JOTEC ($225M acquisition cost, 2017) and On-X (2016)
- Additional intangibles (customer relationships, developed technology, trade names) not separately broken out in XBRL data but estimated at $100–150M gross based on 10-K MD&A
- Artivion's Preservation Services segment carries a portion of goodwill and intangibles — if segment performance deteriorates, a non-cash impairment write-down is possible

**No goodwill impairment has been recorded in the last 3 years.** [S1]

##### Working Capital

| Metric | Dec 2024 | Dec 2025 |
|--------|---------|---------|
| Inventory | $80M | $92M |
| Current Assets | $290M | $358M |
| Current Liabilities | $67M | $102M |
| Working Capital | $223M | $256M |

Inventory build (+$12M YoY) likely reflects NEXUS/AMDS pre-commercial stocking. Current liabilities rose $35M — watch for accounts payable stretch if free cash flow remains constrained.

---

#### 3. Cash Flow Quality

| Metric | FY2023 | FY2024 | FY2025 |
|--------|--------|--------|--------|
| Operating CF | $18.8M | $22.2M | $39.9M |
| Capital Expenditures | $9.8M | $11.2M | $39.0M |
| Free Cash Flow | $9.1M | $11.0M | $0.8M |
| FCF Margin | 2.6% | 2.8% | 0.2% |

**FCF quality concern:** Despite $39.9M in operating cash flow, capex tripled in FY2025 ($39.0M vs. $11.2M). The 10-K attributes this to increased property/equipment investment, likely including Endospan-related preparations and NEXUS manufacturing capacity buildout. If this is a temporary capex peak (the "J-curve" of investment before revenue), FCF should normalize to $25–35M by FY2027–2028 on the current EBITDA trajectory. If capex remains elevated, the FCF story is structurally impaired.

**Operating CF is cleaner:** $39.9M operating CF on $441M revenue = 9% OCF margin — acceptable for a growing med-tech. The OCF-to-net-income gap ($39.9M vs $9.8M GAAP net income) is primarily D&A and SBC addbacks, confirming reported earnings are heavily encumbered by non-cash charges.

---

#### 4. Adversarial Research Sweep

*Per the coverage-next-full path: analysis based on SEC filings, 8-K disclosures, press releases, and web search. No short-seller reports directly located. Key adversarial risks identified:*

##### 4.1 Cybersecurity Incident (Q4 2024)

Artivion disclosed a cybersecurity incident in November 2024 that disrupted ERP systems and operational capabilities. The company disclosed an estimated **-$4.6M revenue impact** in Q4 2024. The incident resulted in: operational disruptions to order processing and billing, possible data access by threat actors, and significant one-time remediation costs. The tissue preservation segment was disproportionately affected. [S1]

**Assessment:** The FY2025 recovery from this trough makes the YoY comparisons look better than the underlying trend. FY2026 will be the first truly clean comparison year. No evidence of ongoing compromise.

##### 4.2 Italian Payback Mechanism

Italy requires medical device companies to rebate a portion of revenues exceeding government budget allocations. Artivion disclosed an estimated **$2.3M liability** for the 2019–2025 period — paid in 2025. Modest in magnitude but illustrates government pricing risk in European markets. [S1]

##### 4.3 Endospan Acquisition Risk

The May 2026 Endospan acquisition re-leverages the balance sheet and concentrates manufacturing of the NEXUS product in a single Israeli facility. Risk factors include: geopolitical disruption to Israel-based operations, integration complexity, and the $200M in contingent payments (milestone-based) that could create significant future cash outflows if NEXUS achieves commercial success thresholds. [S1]

##### 4.4 GLP-1 Secular Risk

Artivion management has acknowledged the long-term risk that GLP-1 drugs (Ozempic, Mounjaro) reducing obesity could decrease cardiovascular disease incidence over the next decade. The company argues its target patient population (complex aortic arch disease, genetic thoracic aortic aneurysms) is largely not obesity-driven — and therefore less exposed than coronary/valvular disease competitors. **Judgment: plausible mitigant but warrants monitoring.** [S1]

##### 4.5 Short Interest / Activist Activity

- Juniper Investment Company (a 13D activist filer) sold approximately 234,000 shares during June–August 2025 at $29.62–$42.36, reducing its position — not a traditional short-seller attack but a significant institutional seller at elevated prices [S5]
- No prominent short-seller reports located targeting AORT specifically as of June 2026
- Oss Capital (~8.1% holder) is classified by some sources as activist-oriented; no public campaign as of research date [S3]

##### 4.6 Financial Reporting Quality Assessment

**PASS** — No restatements, no material weaknesses disclosed, no qualified audit opinion. Reserves and estimates (goodwill, intangible amortization, tissue banking provisions) appear in line with industry norms. XBRL data is consistent with reported financials. Independent auditor: Ernst & Young LLP. [S1]

---

#### 5. Source Index

- **[S1]** 10-K FY2025 — Artivion, Inc.
- **[S2]** XBRL company facts — `xbrl/xbrl_summary.md`
- **[S3]** Governance file — `proxy/governance_and_compensation.md`
- **[S4]** Consensus + guidance — `other/consensus.md`
- **[S5]** Insider transactions — `proxy/insider_transactions.md`

---

*Thesis Tracker Update: Financial quality is adequate. Key risks: (1) capex elevation is temporary hypothesis needs monitoring; (2) Endospan re-leveraging is real and must be modeled; (3) SG&A ratio is high — leverage is key to EPS/FCF normalization. No fraud indicators found. Cybersecurity incident is resolved.*

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/AORT/fundamental

## Navigation

- Overview: /stocks/aort
- Financials (this page): /stocks/aort/financials
- Thesis: /stocks/aort/thesis
- Investment Memo: /memo/aort
- Coverage universe: /stocks